Notice of Intent to Use Other than Full and Open Competition
ID: 75A50120Q00001Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFWashington, DC, 20201, US

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/0ed1ab6f57c84ff8b98df9ed5913cf7b/view
Timeline
    Description

    The Department of Health and Human Services (HHS) intends to award sole source contract modifications to Allucent Government Services and ICON Government and Public Health Solutions, Inc. to support ongoing Phase 2b clinical trials for second generation COVID-19 countermeasures. The modifications will increase the maximum ordering amounts for both contracts by $150 million, raising the total from $400 million to $550 million, in response to FDA changes regarding the updated vaccine formula and the inclusion of a safety lead-in cohort. This procurement is critical for advancing public health initiatives related to COVID-19, with the notice open for responses until September 9, 2024, at 4:00 PM Eastern Standard Time. Interested parties can contact Ely Shannon at ely.shannon@hhs.gov or call 202-579-5891 for further information.

    Point(s) of Contact
    Ely Shannon
    (202) 579-5891
    ely.shannon@hhs.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Use Other than Full and Open Competition
    Currently viewing
    Special Notice
    Similar Opportunities
    RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the development of NextGen Oral Formulation Vaccines for COVID-19 through a Request for Project Proposals (RPP) issued via the Rapid Response Partnership Vehicle (RRPV) Consortium. The primary objective of this solicitation is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, enhancing the understanding of their potential and improving COVID-19 solutions to bolster preparedness against future health security threats. This initiative is critical in the ongoing efforts to combat COVID-19 and prepare for similar health crises. Interested parties can access the full RPP and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    A--Request for Proposals - Phase I Clinical Trials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Phase I clinical trials aimed at developing small molecule and biologics therapeutics, as outlined in RFP No. 75N95024R00086. The selected contractor will be responsible for comprehensive services including protocol development, trial management, and reporting to regulatory agencies, with a focus on safety, tolerability, and pharmacokinetics of the investigational therapeutics. This initiative is crucial for advancing therapeutic development in the field of neurology, ensuring compliance with FDA and ICH GCP standards throughout the trial process. Proposals are due by October 3, 2024, with a contract performance period from April 1, 2025, to March 31, 2035, and a maximum contract value of $233,227,446. Interested parties can contact Evan C. Feely at evan.feely@nih.gov or +1 301 827 5301 for further information.
    Good Manufacturing Practice (GMP)-manufactured Monoclonal Antibody
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to award a sole source contract for the procurement of Good Manufacturing Practice (GMP)-manufactured Monoclonal Antibody UB-421, with a requirement of 100 liters. This procurement is critical for an ongoing clinical trial aimed at treating patients with multidrug-resistant HIV-1 infection, utilizing UB-421, which is exclusively manufactured by United BioPharma, Inc., the sole patent holder and provider of the necessary cell line for production. Interested parties who believe they can meet the specifications must submit a capability statement to the primary contact, Hershea Vance, by 3:00 PM EST on September 20, 2024, as the contract is expected to be awarded within 19 days of this notice, with a performance period from September 23, 2024, to September 24, 2025.
    A--BPCA Pediatric Trials Network
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for an Indefinite Quantity Contract to establish and manage the Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network. This initiative aims to create a robust infrastructure for conducting pediatric clinical trials, emphasizing compliance with federal regulations and ethical standards in research practices. The contract, which has a performance period from May 19, 2025, to May 18, 2033, offers a minimum compensation of $2,500 and a maximum potential value of $149 million, contingent on successful performance. Proposals are due by November 4, 2024, and interested parties can contact Elizabeth J. Osinski at eo43m@nih.gov or 240-550-5028 for further information.
    Pegfilgrastim with VMI
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the procurement of Pegfilgrastim 6MG/.06ML (inj, soln, syr, or autoinjector) along with vendor-managed inventory (VMI) services to support national preparedness against public health emergencies. The contract will span five years, including a one-year base period and four optional ordering periods, with an initial quantity of 18,300 units projected to increase based on public health needs. This procurement is critical for maintaining robust health security capabilities and ensuring efficient supply chain management for essential pharmaceuticals. Interested contractors should direct inquiries to LaMonica Norwood at OSContracting@hhs.gov, with proposals due by the specified deadlines outlined in the RFP documentation.
    HCOREHPOP24
    Active
    Buyer not available
    The U.S. Department of Health and Human Services (HHS) is seeking proposals for a web-based Software as a Service (SaaS) application to enhance the Health Partner Ordering Portal (HPOP), aimed at managing the ordering and distribution of medical countermeasures (MCMs) and public health resources during emergencies. The contractor will be responsible for ensuring compliance with 21CFR Part 11 and providing services that include project management, software development, and analytics support, while also maintaining strict security and operational standards. This procurement is critical for improving the U.S. government's public health response capabilities, particularly in light of recent health crises. Interested small businesses must submit their proposals by September 17, 2024, and can contact Ketwana Wright at Ketwana.Wright@hhs.gov for further information.
    COVID-19 Small Molecule Therapeutics for PrEP
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking proposals for the "COVID-19 Small Molecule Therapeutics for PrEP" initiative. This opportunity invites qualified offerors to submit project proposals via the Rapid Response Partnership Vehicle (RRPV) Consortium, aimed at developing therapeutics for pre-exposure prophylaxis against COVID-19. The initiative is critical in enhancing public health responses and preparedness against the ongoing pandemic. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    COVID-19 PRF and UIP Close-out Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Health Resources and Services Administration (HRSA), is seeking to award a firm fixed price contract for COVID-19 Provider Relief Fund (PRF) and Uninsured Program (UIP) close-out services. The primary objective of this procurement is to finalize activities related to the UIP, ARP Rural, and PRF programs, which includes processing payment returns, supporting healthcare providers, and addressing legal and audit inquiries as these programs wind down. This contract is crucial for ensuring a smooth transition and continuity of services during the ongoing COVID-19 response, utilizing existing contractor systems to minimize operational disruptions. Interested parties may submit their capabilities to Dave Archibald at HRSA by the specified deadline, with the anticipated service commencement set for October 2024 and the contract structured for a six-month base period with two optional twelve-month extensions.
    Amendment No. 1 -Notice of Intent to Award a Sole Source Contract – Radiation Protection Advancing Patient Safety
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), intends to award a Sole Source contract to the National Council on Radiation Protection and Measurements (NCRP) for the project titled "Radiation Protection Advancing Patient Safety." The primary objective of this procurement is to obtain up to six well-sourced scientific analyses, reports, and recommendations on radiation safety, which will inform regulatory decision-making and policy development related to radiological medical devices and radiation-emitting electronic products. This initiative is crucial for enhancing patient safety by ensuring that radiation exposure is minimized and that the quality of patient care is improved. Interested parties must submit their capability statements to Bernice Nelson by September 19, 2024, with the contract being executed under simplified acquisition procedures and the NAICS code 541720, which has a small business size standard of $28 million.